Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 26, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Adverse Pregnancy Outcome
Interventions
DRUG

Lovenox 40mg

Enoxaparin is a blood thinner. It is approved for use in the prevention of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness; inpatient treatment of acute DVT with or without pulmonary embolism; outpatient treatment of acute DVT without pulmonary embolism; Prevention of ischemic complications of unstable angina and non-Q-wave myocardial infarction; treatment of acute ST-segment elevation myocardial infarction(STEMI) managed medically or with subsequent percutaneous coronary intervention. The use of Lovenox has been shown to be safe, and it has also been used widely off-label in pregnancy.

Trial Locations (1)

60201

RECRUITING

NorthShore University HealthSystem, Evanston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Endeavor Health

OTHER